Torrent Pharma Board Approves FY26 Results, Recommends ₹9 Dividend and ₹5,000 Cr QIP.
Torrent Pharmaceuticals approved its FY26 audited financial results. The company recommended a final dividend of ₹9 per share and proposed a QIP of up to ₹5,000 crores. For Q4FY26, revenue was ₹2,735 crore and net profit was ₹467 crore. For FY26, revenue reached ₹10,712 crore with a net profit of ₹2,192 crore.
The approval of financial results, recommendation of a dividend, and the significant QIP proposal are material events that can impact investor sentiment and the company's capital structure.
The company has announced positive financial results, recommended a dividend, and proposed a significant fundraising via QIP, indicating growth and financial health.
Torrent Pharmaceuticals Limited announced the outcome of its Board Meeting held on May 22, 2026. The Board approved the audited financial results for the quarter and year ended March 31, 2026, both on a standalone and consolidated basis. The company declared a final dividend of ₹9 per equity share (180%), with a proposed payment date around June 25, 2026. The record date for this dividend has been fixed as May 29, 2026. Additionally, the Board recommended seeking member approval at the upcoming Annual General Meeting for an equity issuance, including convertible bonds or debentures, through Qualified Institutional Placement (QIP) or other modes, for an amount not exceeding ₹5,000 crores.
The company also reported its financial performance. For the quarter ended March 31, 2026, total revenue from operations stood at ₹2,735 crores, with a net profit of ₹467 crores. For the full year ended March 31, 2026, total revenue from operations was ₹10,712 crores, and net profit was ₹2,192 crores. These results were published with an unmodified audit opinion.
The company also provided details regarding its acquisition of a controlling stake in JB Pharma, which was completed with effect from January 21, 2026. Expenses related to this acquisition have been charged to the Profit and Loss statement. A scheme of amalgamation of JB Pharma into Torrent Pharmaceuticals has been filed with the NCLT.
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.